Healthcare ❯ Pharmaceuticals ❯ Weight Loss Drugs ❯ GLP-1 Drugs

Eli Lilly

Eli Lilly Trades at a High Multiple as GLP‑1 Catalysts Loom

Near‑term regulatory decisions and launch results will determine whether investors’ big growth bet on the company is justified.

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill